Screening and identification of an anti-PD-1 nanobody with antitumor activity
Open Access
- 19 January 2023
- journal article
- research article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 43 (1)
- https://doi.org/10.1042/bsr20221546
Abstract
Blocking of PD-1 or PD-L1 with corresponding antibody to enhance T cell response and mediate antitumor activity has been successfully applied in clinical practice. Several immune checkpoint inhibitors including monoclonal antibodies targeting PD-1 have been approved by the Food and Drug Administration (FDA) in cancer immunotherapy. However, the application of traditional antibodies has limited due to their drawbacks of large molecular weight and low tissue penetration. As the high specificity and strong tissue penetration of nanobodies (Nbs), efforts have been taken to develop Nbs for cancer therapy. Herein, we aim to screen a specific Nb against human PD-1 derived from a naïve camel Nb phage display library and further study its biological characteristic and anti-tumor activity. Finally, an anti-PD-1 Nb with high specificity and affinity was screened and generated, its cytotoxicity and antitumor effect was also confirmed in vitro and vivo. All of these indicate that the anti-PD-1 Nb may provide an alternative and appealing therapeutic agent for cancer immunotherapy.Keywords
This publication has 37 references indexed in Scilit:
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—ResponseClinical Cancer Research, 2013
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Efficient expression of the anti‐AahI' scorpion toxin nanobody under a new functional form in a Pichia pastoris systemBiotechnology and Applied Biochemistry, 2012
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library"Protein Engineering, Design and Selection", 2009
- Isolation and Characterization of a Thermally Stable Recombinant Anti-Caffeine Heavy-Chain Antibody FragmentAnalytical Chemistry, 2006
- Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodiesProceedings of the National Academy of Sciences of the United States of America, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Single‐domain antibody fragments with high conformational stabilityProtein Science, 2002